Matches in SemOpenAlex for { <https://semopenalex.org/work/W4309400534> ?p ?o ?g. }
Showing items 1 to 73 of
73
with 100 items per page.
- W4309400534 endingPage "420" @default.
- W4309400534 startingPage "419" @default.
- W4309400534 abstract "Angiotensin converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARBs) inhibit the renin-angiotensin-aldosterone system (RAAS). The RAAS is an elegant cascade of vasoactive peptides that orchestrates key homeostatic processes [ [1] Mentz R.J. Bakris G.L. Waeber B. McMurray J.J.V. Gheorghiade M. Ruilope L.M. et al. The past, present and future of renin–angiotensin aldosterone system inhibition. Int. J. Cardiol. 2013; 167: 1677-1687 Abstract Full Text Full Text PDF PubMed Scopus (91) Google Scholar ]. In response to hypotension, hypo-osmolality or beta-adrenergic stimulation, the kidneys secrete renin, which cleaves circulating angiotensinogen to angiotensin I. Angiotensin converting enzyme (ACE) catalyses the conversion of angiotensin I into angiotensin II and hydrolyses bradykinin. Angiotensin II acts on AT1 receptors in the arterioles, kidney, adrenal cortex, and brain to stimulate vasoconstriction, sodium reabsorption and thirst; synergistically increasing blood pressure. Overactivity of the RAAS leads to deleterious cardiac remodelling after myocardial infarction and is central to the pathophysiology of hypertension, heart failure, diabetes mellitus and chronic kidney disease. As such, the development of drugs that inhibit the RAAS was a major strategic priority for pharmaceutical companies in the second half of the 20th century. The Utilization, Expenditure, and Price of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in the US Medicaid Programs: Trends Over a 31 Year PeriodInternational Journal of CardiologyVol. 370PreviewAngiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) are used for several indications including hypertension. Our aim is to evaluate the utilization, expenditure, and drug price of ACEIs and ARBs in the US Medicaid population. Full-Text PDF" @default.
- W4309400534 created "2022-11-26" @default.
- W4309400534 creator A5000929297 @default.
- W4309400534 creator A5011497820 @default.
- W4309400534 date "2023-01-01" @default.
- W4309400534 modified "2023-10-16" @default.
- W4309400534 title "Trends in ACEi and ARB expenditure: Compelling case for competition in generic drug markets" @default.
- W4309400534 cites W1994936241 @default.
- W4309400534 cites W2113698123 @default.
- W4309400534 cites W3012285389 @default.
- W4309400534 cites W3029771022 @default.
- W4309400534 cites W3164186626 @default.
- W4309400534 cites W3198728911 @default.
- W4309400534 doi "https://doi.org/10.1016/j.ijcard.2022.11.027" @default.
- W4309400534 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36414045" @default.
- W4309400534 hasPublicationYear "2023" @default.
- W4309400534 type Work @default.
- W4309400534 citedByCount "0" @default.
- W4309400534 crossrefType "journal-article" @default.
- W4309400534 hasAuthorship W4309400534A5000929297 @default.
- W4309400534 hasAuthorship W4309400534A5011497820 @default.
- W4309400534 hasConcept C123915805 @default.
- W4309400534 hasConcept C126322002 @default.
- W4309400534 hasConcept C134018914 @default.
- W4309400534 hasConcept C170493617 @default.
- W4309400534 hasConcept C198710026 @default.
- W4309400534 hasConcept C27016395 @default.
- W4309400534 hasConcept C2778198053 @default.
- W4309400534 hasConcept C2778525890 @default.
- W4309400534 hasConcept C2779591629 @default.
- W4309400534 hasConcept C2780091579 @default.
- W4309400534 hasConcept C2908929049 @default.
- W4309400534 hasConcept C56906281 @default.
- W4309400534 hasConcept C57476199 @default.
- W4309400534 hasConcept C71924100 @default.
- W4309400534 hasConcept C84393581 @default.
- W4309400534 hasConcept C98274493 @default.
- W4309400534 hasConceptScore W4309400534C123915805 @default.
- W4309400534 hasConceptScore W4309400534C126322002 @default.
- W4309400534 hasConceptScore W4309400534C134018914 @default.
- W4309400534 hasConceptScore W4309400534C170493617 @default.
- W4309400534 hasConceptScore W4309400534C198710026 @default.
- W4309400534 hasConceptScore W4309400534C27016395 @default.
- W4309400534 hasConceptScore W4309400534C2778198053 @default.
- W4309400534 hasConceptScore W4309400534C2778525890 @default.
- W4309400534 hasConceptScore W4309400534C2779591629 @default.
- W4309400534 hasConceptScore W4309400534C2780091579 @default.
- W4309400534 hasConceptScore W4309400534C2908929049 @default.
- W4309400534 hasConceptScore W4309400534C56906281 @default.
- W4309400534 hasConceptScore W4309400534C57476199 @default.
- W4309400534 hasConceptScore W4309400534C71924100 @default.
- W4309400534 hasConceptScore W4309400534C84393581 @default.
- W4309400534 hasConceptScore W4309400534C98274493 @default.
- W4309400534 hasLocation W43094005341 @default.
- W4309400534 hasLocation W43094005342 @default.
- W4309400534 hasOpenAccess W4309400534 @default.
- W4309400534 hasPrimaryLocation W43094005341 @default.
- W4309400534 hasRelatedWork W1974641745 @default.
- W4309400534 hasRelatedWork W1975291885 @default.
- W4309400534 hasRelatedWork W1992220075 @default.
- W4309400534 hasRelatedWork W2016647631 @default.
- W4309400534 hasRelatedWork W2024736606 @default.
- W4309400534 hasRelatedWork W2048334412 @default.
- W4309400534 hasRelatedWork W2126797993 @default.
- W4309400534 hasRelatedWork W2151139437 @default.
- W4309400534 hasRelatedWork W2316678200 @default.
- W4309400534 hasRelatedWork W4247631657 @default.
- W4309400534 hasVolume "370" @default.
- W4309400534 isParatext "false" @default.
- W4309400534 isRetracted "false" @default.
- W4309400534 workType "article" @default.